6beta-tosylnaltrexamate | 1166387-58-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 6beta-tosylnaltrexamate
• 英文别名: 17-(cyclopropylmethyl)-3,14-dihydroxy-6β-(((4-methylphenyl)sulfonyl)oxy)-4,5α-epoxymorphinan；[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] 4-methylbenzenesulfonate
• CAS: 1166387-58-1
• 化学式: C₂₇H₃₁NO₆S
• 分子量: 497.612
• InChiKey: YJFFCVFRQOXTKL-KYJCGIAXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-(benzyloxy)-17-(cyclopropylmethyl)-14-hydroxy-6β-(((4-methylphenyl)sulfonyl)oxy)-4,5α-epoxymorphinan 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以80%的产率得到6beta-tosylnaltrexamate
  参考文献：
  名称：

  Design, synthesis, and characterization of 6β-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes

  摘要：

  Since the mu opioid receptor (MOR) is known to be involved in the therapeutically relevant pathways leading to the manifestation of pain and addiction, we are currently studying the specific structural characteristics that promote antagonism at the MOR. The opiates 6 beta-naltrexol and 6 beta-naltrexamide function as neutral antagonists in in vitro and in vivo systems previously exposed to morphine, and are under investigation as improved treatments for narcotic dependence. In this research, we synthesized and characterized carbamate and sulfonate ester derivates of 6 beta-naltrexol that do not contain a protic group at C-6, and evaluated these compounds for opioid receptor affinity. In vitro receptor subtype (mu, kappa, and delta opioid receptors) binding data of the carbamate and sulfonate derivatives is reported. All four compounds synthesized exhibited affinity for the MOR better than the standard 6 beta-naltrexol HCl. Based on K-i data, the order of MOR affinity is as follows: 9 > 13 > 14 > 10 > 6 beta-naltrexol HCl. Carbamate 9 and tosylate 13 displayed subnanomolar affinity for the MOR, while 10 was the most mu-selective compound synthesized. In conclusion, our data indicate that the absence of a hydrogen-bond donor on the C-6 oxygen enhances rather than impedes the in vitro affinity of naltrexol derivatives for the MOR. Additionally, data also suggest that increasing the bulk around C-6 may allow control of subtype selectivity within these compound series. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.095